CALR mutants show an ability to bind common major histocompatibility (MHC) class I proteins, and the co-mutations with SF3B1 showed the highest CALR neoantigen presentation on MHC I variants compared to other MPN mutations, suggesting a potential target for future immunotherapy [112]. Here, CALR is linked to myeloproliferative neoplasm.